Flutisol 250 DPI Capsule is a combination medication containing Salmeterol (50mcg) and Fluticasone Propionate (250mcg), designed for the management of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is a long-acting beta2-adrenergic agonist that helps relax the muscles in the airways, improving airflow and making breathing easier. Fluticasone Propionate is a corticosteroid that reduces inflammation and swelling in the airways, preventing asthma attacks and exacerbations of COPD. Together, these active ingredients provide both bronchodilation and anti-inflammatory effects, offering sustained symptom control and improved lung function. Flutisol 250 DPI Capsule is typically administered via a dry powder inhaler, allowing direct delivery of the medication to the lungs for rapid and effective relief. It is intended for regular use to maintain symptom control and should not be used for immediate relief of acute bronchospasm. Common side effects may include throat irritation, hoarseness, and oral thrush, which can be minimized by rinsing the mouth after inhalation. Patients should follow their healthcare provider’s instructions carefully and report any worsening symptoms or adverse reactions promptly. Flutisol 250 DPI Capsule is a valuable option for long-term respiratory disease management.